The Cocktail Report (sound really smart around your friends):
Life Biosciences, a biotech company co-founded by Harvard's Dr. David Sinclair, received FDA clearance in January 2026 for ER-100, making it the first cellular rejuvenation therapy using epigenetic reprogramming to ever enter human clinical trials.
ER-100 delivers three genes (OCT4, SOX2, and KLF4, abbreviated OSK) into retinal cells via injection, partially resetting their epigenetic age without converting them into stem cells (which would be dangerous).
The trial is targeting patients with glaucoma and a condition called NAION (non-arteritic anterior ischemic optic neuropathy, a form of sudden vision loss caused by blocked blood supply to the optic nerve).
The eye was chosen deliberately: it is an isolated, accessible organ where any problem can be contained, making it the safest possible proof-of-concept for a therapy that could eventually target the liver, heart, kidneys, and beyond.
A doxycycline-controlled "kill switch" allows researchers to turn gene expression on or off, a critical safety design that satisfied FDA requirements.
In primate studies that secured FDA approval, OSK therapy reversed 95% of age-related decline in optic nerve tissue, a result Sinclair described as "stunning."
Sinclair's prediction: "We're not going to have to look at the error bars on the graph. We're going to know if it works or not."
If human results confirm biological age reversal in the eye, the FDA pathway opens for whole-organ trials targeting the liver, heart, and brain.
First patient results are expected by the end of 2026 or early 2027.
For decades, aging research has promised breakthroughs that never quite arrived in the clinic. That changed on January 28, 2026, and the news affects anyone who plans to get older.
Life Biosciences, the Boston biotech co-founded by Harvard genetics professor David Sinclair, announced that the FDA had cleared its Investigational New Drug application for ER-100, a gene therapy designed to partially reset the biological age of human cells. It is the first cellular rejuvenation therapy using epigenetic reprogramming (the process of resetting the chemical tags on DNA that control gene activity) to reach human clinical trials anywhere in the world.
The trial is starting in the eye, and that choice is deliberate. It is an isolated organ where any safety problem can be contained, and where a local injection can reach damaged retinal ganglion cells directly without systemic exposure.
ER-100 delivers three Yamanaka factors (OCT4, SOX2, and KLF4, genes that won a Nobel Prize for reprogramming adult cells) in a controlled, partial way that resets epigenetic age without converting cells into stem cells. A doxycycline-controlled kill switch lets researchers turn gene expression on or off, a safety feature the FDA required before greenlighting the trial.
The preclinical data is what moved the FDA: in non-human primate studies, OSK therapy reversed approximately 95% of age-related decline in optic nerve tissue, a result Sinclair called "stunning." His confidence in human translation rose from roughly 50% to 80 to 90% after seeing those primate results.
Patients with glaucoma and NAION (non-arteritic anterior ischemic optic neuropathy, sudden vision loss from a blocked blood supply to the optic nerve) are now being enrolled, with first results expected by late 2026 or early 2027. The trial is primarily assessing safety, but vision function measurements are being collected throughout.
This matters to you because the eye is just the entry point. A positive result opens the FDA pathway for ER-300 (targeting the liver, already showing strong animal data), and eventually for the heart, brain, and muscle: one successful organ changes the regulatory framework for everything that follows.
Sinclair put it plainly: "We're not going to have to look at the error bars on the graph. We're going to know if it works or not.
Why Should You Care?
This is not a mouse study or a theoretical model. Human patients are being injected right now with a therapy designed to make their cells younger, and results are expected before the end of this year.
A positive outcome would not just be a medical milestone. It would be the moment aging officially became a treatable condition, which is a different world than the one we currently live in.
Citations:
Life Biosciences press release. "Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies." January 28, 2026. https://www.lifebiosciences.com/life-biosciences-announces-fda-clearance-of-ind-application-for-er-100-in-optic-neuropathies/
Fortune. "This startup has the lead in longevity, securing the first FDA human clinical trial." January 30, 2026. https://fortune.com/2026/01/30/billionaires-longevity-aging-fda-human-clinical-trial-life-biosciences-jerry-mclaughlin-david-sinclair-harvard-science/
Lifespan.io. "Life Bio's Trial: Is the FDA Warming to Rejuvenation?" April 8, 2026. https://lifespan.io/life-bios-trial-is-the-fda-warming-to-rejuvenation/
MIT Technology Review. "The first human test of a rejuvenation method will begin 'shortly'." January 27, 2026. https://www.technologyreview.com/2026/01/27/1131796/the-first-human-test-of-a-rejuvenation-method-will-begin-shortly/
Tom Bilyeu / Impact Theory. "AI Just Compressed 160 Years of Aging Research." April 16, 2026. https://www.youtube.com/watch?v=tMYoiHSYgWw
